José Alberto
Orfao de Matos Correia e Vale
Catedrático de Universidad
![Foto de José Alberto](/img/nophoto.png)
![Foto de Hospital Morales Meseguer](/img/noimage_org.png)
Hospital Morales Meseguer
Murcia, EspañaPublicaciones en colaboración con investigadores/as de Hospital Morales Meseguer (23)
2021
-
Adverse prognostic impact of complex karyotype (≥3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL)
Leukemia Research, Vol. 109
-
Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome–negative adult lymphoblastic leukemia
Blood, Vol. 137, Núm. 14, pp. 1879-1894
-
Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia
Leukemia, Vol. 35, Núm. 8, pp. 2358-2370
-
Outcomes and prognostic factors of adults with refractory or relapsed T-cell acute lymphoblastic leukemia included in measurable residual disease-oriented trials
Hematological Oncology, Vol. 39, Núm. 4, pp. 529-538
2020
-
A pediatric regimen for adolescents and young adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: Results of the ALLRE08 PETHEMA trial
Cancer Medicine, Vol. 9, Núm. 7, pp. 2317-2329
-
Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma
Blood, Vol. 135, Núm. 26, pp. 2375-2387
-
Unique clinico-biological, genetic and prognostic features of adult early T-cell precursor acute lymphoblastic leukemia
Haematologica
2019
-
Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis
Leukemia, Vol. 33, Núm. 5, pp. 1256-1267
-
Increased survival due to lower toxicity for high-risk T-cell acute lymphoblastic leukemia patients in two consecutive pediatric-inspired PETHEMA trials
European Journal of Haematology, Vol. 102, Núm. 1, pp. 79-86
2018
-
Efficacy and safety of native versus pegylated Escherichia coli asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemia
Leukemia and Lymphoma, Vol. 59, Núm. 7, pp. 1634-1643
2017
-
Depth of response in multiple myeloma: A pooled analysis of three PETHEMA/GEM clinical trials
Journal of Clinical Oncology, Vol. 35, Núm. 25, pp. 2900-2910
-
Guidelines for diagnosis, prevention and management of central nervous system involvement in diffuse large B-cell lymphoma patients by the Spanish Lymphoma Group (GELTAMO)
Haematologica, Vol. 102, Núm. 2, pp. 235-245
2016
-
Blastic plasmacytoid dendritic cell neoplasm frequently shows occult central nervous system involvement at diagnosis and benefits from intrathecal therapy
Oncotarget, Vol. 7, Núm. 9, pp. 10174-10181
-
Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: A new model to understand chemoresistance
Blood, Vol. 127, Núm. 15, pp. 1896-1906
-
Spanish consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria
Medicina Clinica
2015
-
Critical analysis of the stringent complete response in multiple myeloma: Contribution of sFLC and bone marrow clonality
Blood, Vol. 126, Núm. 7, pp. 858-862
2013
2012
-
Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients
Leukemia, Vol. 26, Núm. 8, pp. 1862-1869
-
Multiparameter flow cytometry evaluation of plasma cell DNA content and proliferation in 595 transplant-eligible patients with myeloma included in the Spanish GEM2000 and GEM2005<65y trials
American Journal of Pathology, Vol. 181, Núm. 5, pp. 1870-1878
2011
-
Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma
Journal of Clinical Oncology, Vol. 29, Núm. 12, pp. 1627-1633